Rhode Island is currently home to 489 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Strategy for Improving Stroke Treatment Response
NCT05948566
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Ischemic Stroke
Register for Updates
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Smilow Cancer Hospital Care Center - Westerly, Westerly, Rhode Island
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Lifespan Rhode Island Hospital, Providence, Rhode Island
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
NCT04667520
Recruiting
The primary aim of this project is to test the efficacy of a technology-supported lifestyle physical activity (LPA) intervention for preventing relapse among women with depression engaged in alcohol treatment. Participants are randomized to either 1) LPA+Fitbit intervention or 2) Fitbit Only control condition. Follow-up assessments and EMA data will be collected.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2025
Locations: Butler Hospital, Providence, Rhode Island
Conditions: Alcohol Use Disorder, Depression
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Smilow Cancer Hospital Care Center - Westerly, Westerly, Rhode Island
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
NCT06480227
Recruiting
This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care. The Primary Aim is to determine the comparative effectiveness (as defined by "much" or "very much" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment interventio... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/02/2025
Locations: Brown/ Women and Infants Hospital of Rhode Island, Division of Urogynecology and Reconstructive Pelvic Surgery, Providence, Rhode Island
Conditions: Stress Urinary Incontinence, Urinary Incontinence, Mixed Urinary Incontinence
Register for Updates
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
NCT05776277
Recruiting
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Fecal Incontinence
Register for Updates
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
NCT05605093
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Rhode Island Hospital (Site 080-036), Providence, Rhode Island
Conditions: COVID-19
Register for Updates
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
NCT05517421
Recruiting
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Site Number - 1556, Warwick, Rhode Island
Conditions: Thyroid Eye Disease
Register for Updates
Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders
NCT05184556
Recruiting
This randomized, controlled effectiveness trial will assess outcomes, implementation, and mechanisms of two psychological treatments for adolescent anorexia nervosa (AN) delivered in the home setting, in the context of community-based mental health. Adolescents with AN-spectrum disorders (n=50) and their caregivers will be randomly assigned to either family-based treatment or integrated family therapy delivered in the home. Caregivers and adolescents will provide data on weight, eating, and puta... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
04/02/2025
Locations: Gateway Healthcare, Pawtucket, Rhode Island
Conditions: Anorexia Nervosa, Eating Disorders
Register for Updates
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia
NCT04811560
Recruiting
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/02/2025
Locations: Maine Health, Providence, Rhode Island
Conditions: Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450
Recruiting
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/01/2025
Locations: Brown University Health, Providence, Rhode Island
Conditions: Advanced Solid Tumors Cancer, MSI-H Cancer
Register for Updates